Metabolix competitors

PHARMACEUTICAL EXECUTIVE WITH GLOBAL IMPACTIncreasing stakeholder value and meeting the needs of patients around the world.For over 25 years, I have increased profits and expanded market share for organizations in the pharmaceutical industry-from “big pharma” corporations to small biotech firms. Starting out in sales, I advanced over time to President of Bayer’s U.S. Pharmaceuticals organization. I currently serve as President and CEO of Acceleron Pharma, a public company.My work as an operations and commercial executive spans geographical regions, drug classes (small molecules, biologics), and therapeutic areas, including cardiovascular disease, hematology, neurology, neuromuscular, oncology, ophthalmology, pulmonary, and women’s health. Year after year, my teams have broken new ground by launching blockbuster brands, penetrating new markets, and outperforming sales expectations in competitive regions. Career Highlights:● Propelled Acceleron to a new stage of growth and shareholder value by pivoting the formerly research-focused company toward innovation and pre-commercialization. Increased stock performance vs the biotech index in 2017 & 2018, and positioned the company to potentially launch its first blockbuster drug in 2019.● Structured international organizations and revitalized teams, operations, and brand perceptions to navigate industry changes and exceed performance goals for Bayer AG.● Negotiated deals, such as the agreement between Bayer and Orion Corporation; managed partnerships including Genzyme, Orion Corporation, and Regeneron Pharmaceuticals.● Launched billion-dollar products, including Eylea®, Stivarga®, and Xofigo®, and positioned mature brands such as Betaferon®, Kogenate®, and Nexavar® for heightened success.I attribute my success to the determination, expertise, and hard work of my teams. It is a true privilege to work together in the quest to develop patient-centric organizations that deliver life-changing medications globally.

Robert was appointed President and Chief Executive Officer of Cytokinetics in January 2007 and has been a member of our Board of Directors since then. Previously, he served as Cytokinetics’ President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert has served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. He served on the National Board of the American Committee of the Weizmann Institute of Science and established the Blum Family Venture Philanthropy Fund to propel basic science discoveries at the Institute with potential to benefit the Israeli life sciences economy. In addition, he established the Tikkun Olam Youth Science Prizes for Bay Area middle and high schools, designed to further science education and exploration in the spirit of repairing the world. Robert served on the Board of the Jewish Community Federation of San Francisco and founded and chaired its Business Leadership Council. He also served on the Boards of San Francisco’s Contemporary Jewish Museum and the Anti-Defamation League. Robert was named a Henry Crown Fellow of the Aspen Institute in recognition of his leadership in corporate and civic responsibilities. He is a member of the Aspen Global Leadership Network and has moderated seminars related to science, health, and technology at Aspen Action Forums. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Robert was a fan of mountain bluegrass music long before it was fashionable and has been known to carry a harmonica in his briefcase, much to the dismay of nearby hotel guests. He enjoys trying to keep up with his wife Dana and daughters, Brittany and Bridget, as well as his Bernese mountain dog, Baron, on long hikes in the Presidio.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Rick Winningham has served as a member of our Board of Directors since May 2010. Since 2001, he has served as the Chief Executive Officer and a member of the Board of Directors of Theravance, Inc., a biopharmaceutical company, and in April 2010, he was appointed Chairman of the Board of Directors. From 1997 to 2001, he served as President of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000 to 2001, as President of Global Marketing. He is a member of the board of directors of the California Healthcare Institute (CHI) and is also a member of the External Advisory Board for the College of Business and Administration and Business Hall of Fame at Southern Illinois University.Rick Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University.

David Shanahan is a Chairman of the Board at G-CON Manufacturing, Managing Director at Endurance Capital, and Chairman Of The Board at Lab7 Systems and is based in Dallas, Texas. He has worked as President at Mary Crowley Cancer Research Center. David attended Texas A&M University between 1981 and 1985.